vs
渤健（BIIB）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
RYDER SYSTEM INC的季度营收约是渤健的1.3倍（$3.1B vs $2.5B），渤健净利率更高（12.9% vs 3.0%，领先9.9%），渤健同比增速更快（2.0% vs 1.0%），渤健自由现金流更多（$594.3M vs $273.0M），过去两年渤健的营收复合增速更高（0.3% vs -0.9%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
BIIB vs R — 直观对比
营收规模更大
R
是对方的1.3倍
$2.5B
营收增速更快
BIIB
高出1.0%
1.0%
净利率更高
BIIB
高出9.9%
3.0%
自由现金流更多
BIIB
多$321.3M
$273.0M
两年增速更快
BIIB
近两年复合增速
-0.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $3.1B |
| 净利润 | $319.5M | $93.0M |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | 12.9% | 3.0% |
| 营收同比 | 2.0% | 1.0% |
| 净利润同比 | 32.8% | -5.1% |
| 每股收益（稀释后） | $2.15 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBR
| Q1 26 | $2.5B | $3.1B | ||
| Q4 25 | $2.3B | $3.2B | ||
| Q3 25 | $2.5B | $3.2B | ||
| Q2 25 | $2.6B | $3.2B | ||
| Q1 25 | $2.4B | $3.1B | ||
| Q4 24 | $2.5B | $3.2B | ||
| Q3 24 | $2.5B | $3.2B | ||
| Q2 24 | $2.5B | $3.2B |
净利润BIIBR
| Q1 26 | $319.5M | $93.0M | ||
| Q4 25 | $-48.9M | $132.0M | ||
| Q3 25 | $466.5M | $138.0M | ||
| Q2 25 | $634.8M | $131.0M | ||
| Q1 25 | $240.5M | $98.0M | ||
| Q4 24 | $266.7M | $135.0M | ||
| Q3 24 | $388.5M | $142.0M | ||
| Q2 24 | $583.6M | $127.0M |
毛利率BIIBR
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBR
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 5.6% | ||
| Q3 25 | 22.0% | 6.0% | ||
| Q2 25 | 28.1% | 5.8% | ||
| Q1 25 | 12.8% | 4.3% | ||
| Q4 24 | 11.9% | 5.7% | ||
| Q3 24 | 18.3% | 5.9% | ||
| Q2 24 | 28.3% | 5.6% |
净利率BIIBR
| Q1 26 | 12.9% | 3.0% | ||
| Q4 25 | -2.1% | 4.2% | ||
| Q3 25 | 18.4% | 4.4% | ||
| Q2 25 | 24.0% | 4.1% | ||
| Q1 25 | 9.9% | 3.1% | ||
| Q4 24 | 10.9% | 4.2% | ||
| Q3 24 | 15.8% | 4.5% | ||
| Q2 24 | 23.7% | 4.0% |
每股收益（稀释后）BIIBR
| Q1 26 | $2.15 | $2.34 | ||
| Q4 25 | $-0.35 | $3.22 | ||
| Q3 25 | $3.17 | $3.32 | ||
| Q2 25 | $4.33 | $3.13 | ||
| Q1 25 | $1.64 | $2.27 | ||
| Q4 24 | $1.82 | $3.09 | ||
| Q3 24 | $2.66 | $3.24 | ||
| Q2 24 | $4.00 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.4B | $182.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $18.7B | $2.9B |
| 总资产 | $29.5B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBR
| Q1 26 | $3.4B | $182.0M | ||
| Q4 25 | — | $198.0M | ||
| Q3 25 | — | $189.0M | ||
| Q2 25 | — | $180.0M | ||
| Q1 25 | — | $151.0M | ||
| Q4 24 | — | $154.0M | ||
| Q3 24 | — | $162.0M | ||
| Q2 24 | — | $164.0M |
总债务BIIBR
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | $6.8B | ||
| Q3 25 | $6.3B | $7.3B | ||
| Q2 25 | $6.3B | $7.0B | ||
| Q1 25 | $4.5B | $6.7B | ||
| Q4 24 | $6.3B | $6.7B | ||
| Q3 24 | $4.5B | $6.6B | ||
| Q2 24 | $6.3B | $6.5B |
股东权益BIIBR
| Q1 26 | $18.7B | $2.9B | ||
| Q4 25 | $18.3B | $3.1B | ||
| Q3 25 | $18.2B | $3.1B | ||
| Q2 25 | $17.6B | $3.1B | ||
| Q1 25 | $17.0B | $3.0B | ||
| Q4 24 | $16.7B | $3.1B | ||
| Q3 24 | $16.4B | $3.1B | ||
| Q2 24 | $15.9B | $3.1B |
总资产BIIBR
| Q1 26 | $29.5B | — | ||
| Q4 25 | $29.4B | $16.4B | ||
| Q3 25 | $29.2B | $16.5B | ||
| Q2 25 | $28.3B | $16.5B | ||
| Q1 25 | $28.0B | $16.4B | ||
| Q4 24 | $28.0B | $16.7B | ||
| Q3 24 | $28.3B | $16.5B | ||
| Q2 24 | $26.8B | $16.4B |
负债/权益比BIIBR
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | 2.24× | ||
| Q3 25 | 0.35× | 2.35× | ||
| Q2 25 | 0.36× | 2.27× | ||
| Q1 25 | 0.27× | 2.21× | ||
| Q4 24 | 0.38× | 2.14× | ||
| Q3 24 | 0.28× | 2.17× | ||
| Q2 24 | 0.40× | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $583.0M |
| 自由现金流经营现金流 - 资本支出 | $594.3M | $273.0M |
| 自由现金流率自由现金流/营收 | 24.0% | 8.7% |
| 资本支出强度资本支出/营收 | — | 13.7% |
| 现金转化率经营现金流/净利润 | — | 6.27× |
| 过去12个月自由现金流最近4个季度 | $2.4B | $595.0M |
8季度趋势，按日历期对齐
经营现金流BIIBR
| Q1 26 | — | $583.0M | ||
| Q4 25 | $511.9M | $749.0M | ||
| Q3 25 | $1.3B | $442.0M | ||
| Q2 25 | $160.9M | $752.0M | ||
| Q1 25 | $259.3M | $651.0M | ||
| Q4 24 | $760.9M | $558.0M | ||
| Q3 24 | $935.6M | $629.0M | ||
| Q2 24 | $625.8M | $552.0M |
自由现金流BIIBR
| Q1 26 | $594.3M | $273.0M | ||
| Q4 25 | $468.0M | $344.0M | ||
| Q3 25 | $1.2B | $-85.0M | ||
| Q2 25 | $134.3M | $63.0M | ||
| Q1 25 | $222.2M | $137.0M | ||
| Q4 24 | $721.6M | $-201.0M | ||
| Q3 24 | $900.6M | $30.0M | ||
| Q2 24 | $592.3M | $-87.0M |
自由现金流率BIIBR
| Q1 26 | 24.0% | 8.7% | ||
| Q4 25 | 20.5% | 10.8% | ||
| Q3 25 | 48.4% | -2.7% | ||
| Q2 25 | 5.1% | 2.0% | ||
| Q1 25 | 9.1% | 4.4% | ||
| Q4 24 | 29.4% | -6.3% | ||
| Q3 24 | 36.5% | 0.9% | ||
| Q2 24 | 24.0% | -2.7% |
资本支出强度BIIBR
| Q1 26 | — | 13.7% | ||
| Q4 25 | 1.9% | 12.8% | ||
| Q3 25 | 1.8% | 16.6% | ||
| Q2 25 | 1.0% | 21.6% | ||
| Q1 25 | 1.5% | 16.4% | ||
| Q4 24 | 1.6% | 23.8% | ||
| Q3 24 | 1.4% | 18.9% | ||
| Q2 24 | 1.4% | 20.1% |
现金转化率BIIBR
| Q1 26 | — | 6.27× | ||
| Q4 25 | — | 5.67× | ||
| Q3 25 | 2.73× | 3.20× | ||
| Q2 25 | 0.25× | 5.74× | ||
| Q1 25 | 1.08× | 6.64× | ||
| Q4 24 | 2.85× | 4.13× | ||
| Q3 24 | 2.41× | 4.43× | ||
| Q2 24 | 1.07× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
R
| Fleet Management Solutions | $1.5B | 47% |
| ChoiceLease | $878.0M | 28% |
| Dedicated Transportation Solutions | $553.0M | 18% |
| Commercial rental | $211.0M | 7% |
